Found 706 clinical trials
UPCC#01409: Lintuzumab-Ac225 in Older Patients with Untreated AML
This is a phase 1/2 study of a radio-labeled investigational drug, 225Ac-lintuzumab, given in combination with low-dose cytarabine in previously untreated elderly patients with AML. Phase 1 will establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside, and Phase 2 will help determine the …
An Exploratory Case-Control Study of Genetic and Clinical Factors For Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate With New Medications taken for atleast 3 months prior to the study
Eslicarbazepine acetate (Aptiom®) is an antiepileptic drug (AED) approved in the United States (US) as adjunctive therapy for the treatment of partial-onset seizures in adults .Prior research has shown that seizure medicines like carbamazepine (Tegretol®) and oxcarbazepine (Trileptal®, Oxtellar®) are more likely to cause severe drug related skin reactions in …
Cerebrovascular reactivity assessed with functional near-infrared spectroscopy as a biomarker of traumatic microvascular injury after traumatic brain injury
Traumatic cerebrovascular injury (TCVI) is common after traumatic brain injury (TBI) and an attractive target for therapeutic intervention. We will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to …
UPCC 24116: A Phase II Pilot Trial of Hydroxychloroquine Everolimus or the Combination for Prevention of Recurrent Breast Cancer
The main purpose of this study is to: 1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow. 2) determine how tolerable these drugs are in people who have completed treatment for breast cancer. 3) determine how well …
Transforming Research and Clinical Knowledge in Traumatic Brain Injury
Traumatic brain injury (TBI) is among the leading causes of death and disability worldwide with enormous social and economic impacts. The heterogeneity of TBI, combined with the lack of precise outcome measures, have been central to the discouraging results from numerous clinical trials. Current approaches to the characterization of disease …
Post Market Clinical Follow Up Evaluating the Infinity Deep Brain Stimulation Implantable Pulse Generator System (PROGRESS)
You are being invited to participate in a research study because you have been diagnosed with Parkinson’s disease (PD) and you underwent or have been offered a procedure called Deep Brain Stimulation (DBS) as a treatment option to manage some of your symptoms of Parkinson’s disease. The purpose of this …
UPCC 31216: Phase I/II Trial of Regorafenib Hydroxychloroquine and Entinostat in Metastatic Colorectal Cancer
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis
The main purpose of this study is to see if an experimental drug, TRADIPITANT can help people with diabetic or idiopathic gastroparesis who are suffering from nausea.
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
Request for collaborative review: WIRB serving as IRB of record.
UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma
Request for collaborative review: WIRB serving as IRB of record.
